Palvella Therapeutics Inc
PVLA
View Detailed Chart
113.710USD
+1.340+1.19%
Market hours （ET）Quotes delayed by 15 min
41.62MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.19%
5 Days
+1.08%
1 Month
-15.78%
6 Months
+82.67%
Year to Date
+8.64%
1 Year
+304.66%
View Detailed Chart
TradingKey Stock Score of Palvella Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Palvella Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 69 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 224.94.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Palvella Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Palvella Therapeutics Inc Highlights
StrengthsRisks
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Undervalued
The company’s latest PE is -44.72, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 9.67M shares, increasing 20.45% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 50.55K shares of this stock.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
224.938
Target Price
+91.26%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Palvella Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Palvella Therapeutics Inc Info
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Ticker SymbolPVLA
CompanyPalvella Therapeutics Inc
CEOKaupinen (Wesley H)
Websitehttps://palvellatx.com/
Related Instruments
-0.68%
+1.29%
+0.69%
+3.01%
-0.68%
+0.72%
+1.24%
-0.89%
+0.49%
-0.63%
-2.62%
+0.01%
+0.70%
+0.59%
-3.01%
0.00%
+0.19%
-0.48%
+1.25%
-1.52%Popular Symbols
246.576
-6.314 (-2.50%)
167.700
+0.180 (+0.11%)
67635.420
+1051.370 (+1.58%)
258.695
-16.645 (-6.05%)
2067.500
+67.500 (+3.38%)
363.910
+2.080 (+0.57%)
4538.370
+45.850 (+1.02%)
101.692
+1.083 (+1.08%)
1.145
-0.005 (-0.47%)
159.585
-0.667 (-0.42%)
